SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has announced the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo. The program utilizes the company's SSi Mantra 3.0 surgical robotic system, according to a recent company video. This development represents a notable expansion of robotic-assisted cardiac care into new geographic markets and underscores the growing global adoption of the SSi Mantra platform.
The inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This collaboration highlights the company's hands-on approach to supporting new programs and training local surgeons. In the three weeks following the program's launch, Kings Hospital has completed more than 25 robotic procedures, indicating rapid early adoption and a strong foundation for the program's future growth.
SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter, demonstrating a steady expansion of its global footprint. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528. This sharp rise in procedure volume points to rising utilization of the company's installed base, a key metric for long-term recurring revenue and clinical adoption. For the healthcare industry, these figures suggest that robotic surgery is transitioning from early adoption to broader standardization in multiple markets.
The next major corporate milestone for SS Innovations is regulatory expansion, as the company pursues U.S. FDA clearance and European CE marking for the SSi Mantra system. Success in these highly regulated markets could significantly broaden the company's addressable market and accelerate adoption among hospitals in North America and Europe. For patients, this may translate into greater access to minimally invasive robotic cardiac and other surgical procedures, potentially leading to shorter recovery times and improved outcomes. For investors, the regulatory progress and procedure growth are critical indicators of the company's ability to scale and compete in the global surgical robotics market.
The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. Forward-looking statements in this article involve risks and uncertainties that could cause actual results to differ materially. Undue reliance should not be placed on such statements. For full terms of use and disclaimers, please see https://IBN.ai/Disclaimer.
